 BETHESDA, Md., June 21, 2022 GLOBE NEWSWIRE -- Synlogic, Inc. Nasdaq: SYBX, a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced it will participate in the HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation 2022 Conference, in Bethesda, Maryland, June 25-26, 2022. Synlogic has been invited to present a poster to patients and families affected by homocystinuria HCU regarding SYNB1353, an investigational oral therapy designed to consume methionine for the potential treatment of HCU. 